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Abstract
Background: IBS affects 10-22% of the UK population. Abdominal pain, bloating and altered bowel habit affect
quality of life, social functioning and time off work. Current GP treatment relies on a positive diagnosis, reassurance,
lifestyle advice and drug therapies, but many suffer ongoing symptoms.
A recent Cochrane review highlighted the lack of research evidence for IBS drugs. Neither GPs, nor patients have
good evidence to inform prescribing decisions. However, IBS drugs are widely used: In 2005 the NHS costs were
nearly £10 million for mebeverine and over £8 million for fibre-based bulking agents. CBT and self-management
can be helpful, but poor availability in the NHS restricts their use. We have developed a web-based CBT self-
management programme, Regul8, based on an existing evidence based self-management manual and in partner-
ship with patients. This could increase access with minimal increased costs.
Methods/Design: The aim is to undertake a feasibility factorial RCT to assess the effectiveness of the commonly
prescribed medications in UK general practice for IBS: mebeverine (anti-spasmodic) and methylcellulose (bulking-
agent) and Regul8, the CBT based self-management website.
135 patients aged 16 to 60 years with IBS symptoms fulfilling Rome III criteria, recruited via GP practices, will be
randomised to 1 of 3 levels of the drug condition: mebeverine, methylcellulose or placebo for 6 weeks and to 1 of
3 levels of the website condition, Regul8 with a nurse telephone session and email support, Regul8 with minimal
email support, or no website, thus creating 9 groups.
Outcomes: Irritable bowel symptom severity scale and IBS-QOL will be measured at baseline, 6 and 12 weeks as
the primary outcomes. An intention to treat analysis will be undertaken by ANCOVA for a factorial trial.
Discussion: This pilot will provide valuable information for a larger trial. Determining the effectiveness of
commonly used drug treatments will help patients and doctors make informed treatment decisions regarding drug
management of IBS symptoms, enabling better targeting of treatment. A web-based self-management CBT
programme for IBS developed in partnership with patients has the potential to benefit large numbers of patients
with low cost to the NHS. Assessment of the amount of email or therapist support required for the website will
enable economic analysis to be undertaken.
Trial Registration: ClinicalTrials.gov Identifier (NCT number): NCT00934973.
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Irritable bowel syndrome (IBS) is a common chronic
gastrointestinal disorder that affects 10 - 22% of the UK
population and costs the National Health Service (NHS)
over 200 million pounds a year [1,2]. Abdominal pain,
bloating and altered bowel habit affect quality of life,
social functioning and time off work [3,4]. Treatment
relies on a positive diagnosis, reassurance, lifestyle
advice, and drug and psychological therapies. However,
many patients suffer ongoing symptoms. Drug treatment
includes: anti-spasmodics, dietary fibre/bulking agents,
antidepressants and anti-diarrhoeals. Bulking agents and
antispasmodics and are the most commonly prescribed
medications in the UK and Europe. Newer ‘5HT’
antagonist drugs, such as alosetron, have been developed
over recent years and used in the U.S.A. but have been
hampered by problematic side effects such as ischaemic
colitis and severe constipation [5] and are not licenced
in the UK. There is a significant psychological aspect to
IBS in many patients and psychological therapies, CBT,
biofeedback and hypnotherapy can help [6], but avail-
ability of these treatments is limited.
A recent Cochrane review [7] highlighted the lack of
evidence for the current drug management. Most stu-
dies were undertaken a long time ago, are of poor qual-
ity, with small numbers, in a secondary care setting. It
found benefit for anti-spasmodics for abdominal pain
and global assessment of symptoms as a class but said it
was unclear whether individual antispasmodic were
effective. Only 2 eligible studies [8,9] were found for
mebeverine (the most used antispasmodic in the UK)
and these failed to show any significant benefit. This
may be due to poor design and small numbers. Meta-
analysis of the trials on bulking agents also failed to
show any significant benefit for in IBS in the Cochrane
review [7] or in other published reviews [2,10]. The lack
of good quality research into the ‘classic’ drugs for IBS
has also been highlighted in guidelines for IBS, i.e. The
British Society of Gastroenterology guidelines for the
Management of Irritable Bowel Syndrome [3]. Thus,
neither doctors nor patients have good evidence to
inform prescribing decisions. However, IBS drugs are
recommended in the guidelines [3,11] and widely used.
In 2005, NHS costs were nearly £10 million for mebe-
verine and over £8 million for fibre-based bulking agents
(Prescription Cost Analysis figures). A large well con-
ducted trial of mebeverine and a fibre-based bulking
agent is needed to provide evidence for prescribing in
IBS.
Face to face Cognitive Behavioural Therapy (CBT) has
been shown to be helpful for IBS reducing symptom
scores and improving QOL measures [6,12] but avail-
ability in primary care is limited and CBT in this format
has not been found to be cost effective (McCrone P,
Knapp M, Kennedy T, Darnley S, Seed P, Jones R et al:
Cost effectiveness of cognitive behaviour therapy in
addition to mebeverine for irritable bowel syndrome,
submitted). Additionally there are problems with high
drop out rates (McCrone P, Knapp M, Kennedy T,
D a r n l e yS ,S e e dP ,J o n e sRet al: Cost effectiveness of
cognitive behaviour therapy in addition to mebeverine
for irritable bowel syndrome, submitted).
Web-based CBT has been shown to be helpful for
other conditions e.g. depression [13] and tinnitus [14].
Thus this could be an efficient, cost effective way of
providing help to those with IBS. Despite extensive lit-
erature searching before the start of the study, we
found no published evaluations of computer-based
CBT programmes for IBS. The Gut Trust (formerly
called the IBS network) (a patient self-help group) pro-
vides an on-line self-management programme (at a
charge) but this is not CBT-based and has not been
critically evaluated in a trial. NICE has recently recom-
mended the use of Computer CBT for depression,
panic and phobia in Primary Care [15]. Development
and testing of a computerised CBT programme for IBS
has the potential to make CBT more widely available
for IBS without increased costs. The increasing avail-
ability of the internet makes this a good medium to
provide easily accessible patient information and self-
management programmes. The majority of households
in the UK have internet access (Office for National
Statistics August 2009) with figures increasing each
year currently 70% have access and this an increase of
11% on the previous year.
Background to the Project
Over the last year we developed a web-based CBT self-
management programme for IBS based on a paper-
based manual [16] that was originally developed and
tested by one of our team in a RCT of 70 patients in
primary care (RMM) [17]. As each module was devel-
oped think aloud [18] interviews were undertaken with
four patients with IBS whilst they worked through the
programme to ensure that the website addressed issues
important to people with IBS and was relevant, under-
standable, navigable and user friendly. The interviews
were transcribed verbatim and the feedback was used to
modify the site as it was developed.
The website was created using the LifeGuide software
[19], which allows people without a programming back-
ground to create web-delivered interactive interventions.
The web-based intervention we developed consists of 8
sessions for participants to work through over 6 weeks
(see table 1 for an overview of each session) and
includes interactive components such as: the develop-
ment of a personal model, creating symptom diaries,
goal sheets and thought records. Interactive components
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“substitute” for the therapist and personalises pro-
gramme to user [19] This enables users to focus on per-
sonally relevant aspects of the programme. Early in each
session participants review key points from the previous
session and review participant homework. The website
includes a ‘My Tasks’ Section that records participant
previous answers and homework.
Aims
To pilot a factorial RCT to assess the effectiveness of
the prescribed medications in UK general practice for
IBS: mebeverine (an anti-spasmodic) and methylcellu-
lose (bulking-agent) against placebo and Regul8, a CBT
based self-management website for IBS developed speci-
fically for this study.
The pilot will provide information for a definitive trial
and all the trial procedures will be tested. The results of
the pilot will enable decisions to be made regarding the
full trial. For example:
1) Is it appropriate to test a fibre-based bulking agent
in all groups of IBS patient (i.e. in those with diarrhoea
symptoms and alternating symptoms as well as those
with constipation symptoms)? Most guidelines advocate
bulking agents for those with constipation symptoms to
increase stool weight and accelerate gut transit [3,11].
The position in those with alternating or diarrhoea symp-
toms is less certain - increasing stool bulk may stabilise
bowel habit and reduce pain or may exacerbate loose
stools - trials have tested bulking agents in IBS patients
with all 3 patterns of bowel habit and symptom exacerba-
tion seems rare [4,8,20,21]. However, if the results of the
pilot show that methylcellulose may significantly worsens
symptoms in those with diarrhoea then this group will
not be randomised to methylcellulose in the full trial.
2) Should the full trial test the website with minimal
email support on request or with the scheduled tele-
phone nurse consultation after session two plus the
minimal email support?
Methods/Design
Design
Placebo controlled randomised controlled trial with a 3
(drug) × 3 (self-management website) factorial design
Table 1 Summary of the Regul8 Web-Based Self-Management Sessions
Session 1:
Understanding your IBS
Rationale for self-management which includes the following explanations:
1. Possible causes of IBS and illustrative physiology of the digestive system together with the functional changes that
occur in the gut as a result of IBS.
2. How the autonomic nervous system ("fight-or-flight” stress system) may interact with the enteric nervous system
Session 2:
Assessing your symptoms
Self-assessment of the interaction between thoughts, feeling and behaviours and how these can impact on stress
levels and gut symptoms.
Development of a personal model of IBS which incorporates these elements.
Homework: Daily diaries of the severity and experience of IBS symptoms in conjunction with stress levels and eating
routines/behaviours
Session 3.
Managing Symptoms and
Eating
Review of the symptom diary
Behavioural management of the symptoms of diarrhoea and constipation, and common myths in this area are
discussed. Goal setting is explained.
The importance of healthy, regular eating and not being overly focused on elimination is covered.
Homework: Goal setting for managing symptoms and regular/healthy eating. Goal setting, monitoring and evaluation
continue weekly throughout the programme.
Session 4.
Exercise and Activity
Importance of exercise in symptom management is covered
Identifying activity patterns such as resting too much in response to symptoms or an all-or-nothing style of activity is
addressed.
Homework: Goal setting for regular exercise and managing unhelpful activity patterns if relevant.
Session 5.
Identifying your thought
patterns
Identifying unhelpful thought (negative automatic thoughts) in relation to high personal expectations and IBS
symptoms is introduced.
Link between these thoughts, feelings, behaviours and symptoms is reinforced.
Homework: Goal setting plus daily thought records of unhelpful thoughts related to personal expectations and
patterns of over activity.
Session 6.
Alternative thoughts
The steps for coming up with alternatives to unhelpful thoughts are covered together with personal examples.
Homework: Goal setting plus daily thought records including coming up with realistic alternative thoughts.
Session 7.
Managing Stress and Sleep
Basic stress management and sleep hygiene are discussed.
Diaphragmatic breathing, progressive muscle relaxation and guided imagery relaxation are presented in video and
audio formats.
Homework: Goal setting for stress management, relaxation techniques and good sleep habits.
Session 8.
Managing flare-ups and the
future
The probability of flare-ups is discussed and patients are encouraged to develop achievable, long term goals and to
continue to employ the skills they have learnt throughout the manual to manage flare-ups and ongoing symptoms.
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Inclusion criteria are patients aged 16 to 60 years pre-
senting to general practice with symptoms of IBS that
fulfil the Rome III criteria (maximum age 60 years as
NICE guidelines advise that a new change in bowel
habit in over 60 year olds should have further investiga-
tions [11])
Exclusion criteria
Atypical symptoms - (unexplained weight loss, rectal
bleeding), diagnosis of inflammatory bowel disease, Coe-
liac disease or peptic ulcer disease, pregnant or breast
feeding, currently taking or allergy to mebeverine or
methylcellulose. If patients are already taking mebever-
ine or methlycellulose but are keen to enter the trial
they will be able to do so if they fulfil the inclusion cri-
teria, do not meet any of the other exclusion criteria
and they undertake a 4 week mebeverine and methylcel-
lulose free wash out period before entering the trial.
Withdrawal criteria
Participants will be withdrawn from the trial if there are
any safety concerns regarding continuing the trial medi-
cation, if there are any concerns regarding informed
consent or if the participant chooses to withdraw.
Recruitment
Patients will be identified by searching general practi-
tioners’ lists for those with a diagnosis of IBS and by
opportunistic recruitment of patients presenting with
symptoms consistent with IBS. We will utilise the Eng-
lish Primary Care network (PCRN) to aid recruitment
and retention of GP practices. We will include practices
with urban and rural settings and with a range of socio-
demographic characteristics. GP practices willing to par-
ticipate in the study will search their list for patients
aged 16 to 60 with a diagnosis of IBS. Potential partici-
pants will be contacted by letter (sent by the GP sur-
gery) informing them about the trial and inviting them
to take part. The GPs will check the lists of patients to
be contacted prior to the invite letters being sent out to
ensure that it is appropriate to contact them. The mail-
ing will include the MIBS patient information sheet.
Participants who are interested in participating in the
study will return a reply slip with their contact details in
a prepaid response envelope to the research team. The
reply slip will also enclose a decline sheet where the
participants can tick the option that describes the rea-
s o n sw h yt h e yh a v ed e c i d e dt od e c l i n et h ei n v i t a t i o n .
GPs will also be able to opportunistically provide infor-
mation about the trial to potential recruits during their
GP surgeries. If a patient with IBS attends a GP consul-
tation, GPs will give them the patient information sheet
regarding the trial and the reply slip and envelope.
Intervention
135 patients will be randomised to: mebeverine (135 mg
three times a day), methylcellulose (3 tablets twice a day),
or a placebo tablet for 6 weeks. To ensure double blind-
ing, all participants will take three over-encapsulated
identical tablets in the morning, one at lunchtime and
three at teatime.
They will also be randomised to 1 of 3 website condi-
tions: access to Regul8 with a 30-45 minute nurse tele-
phone session after session 2 (to encourage engagement
with the CBT programme) and email support on
request, the website with minimal support (i.e. technical
email support on request), or no website, thus creating
9 groups.
There will be double-blinding for medication groups,
single-blinding for the website (participants will not be
able to be blind to website access). Website access will
be with a personal password so that usage can be
assessed. All patients will receive a telephone call in the
first week to check they have no problems with the
medication or paperwork. Those not randomised to
website access will receive standard patient information
and will be offered access to the website at the end of
the trial.
Telephone session
The telephone session in the first website condition will
be scheduled after patients complete session 2 where
they develop their own personal model on the website of
how their thoughts, feelings and behaviours might
be contributing to their IBS symptoms. The purpose of
the session is for the patients to clarify their model with
the nurse, for the nurse to help patients extend their
model where they may have left out relevant material,
and to motivate patients to continue using the website by
linking the sessions back to the information they provide.
Patients will also be given the opportunity to discuss any
technical difficulties they may have and encouraged to
email the nurse if they wish to clarify any information on
the site or have any difficulties in the future.
Prior to the start of the trial the nurse received
4 hours training in the telephone protocol which
included outlining the protocol, training in the basic
principles of CBT and listening skills, practice role play
sessions which were audiotaped and discussed in super-
vision sessions with RMM. All sessions will be audio-
taped and saved in password protected anonymous files.
Throughout the trial, audiotapes will be sent to RMM
and the nurse will receive regular supervision (after each
session for the first 4 sessions and 4 random sessions
thereafter. This will ensure the quality the intervention
as well as allow us to assess fidelity regarding the proto-
col. The timing and length of each telephone session
will be recorded, as well as the number of email
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only conditions.
Trial medication
Will be over-encapsulated active mebeverine 135 mg
tablets, over-encapsulated active methylcellulose 500 mg
tablets and over-encapsulated placebo (candarel) tablets
all to be taken orally. All patients will receive medica-
tions of the same shape and colour. The patients will be
supplied with 6 weeks of medication by the research
nurse. To ensure double blinding, all participants will
take 3 over-encapsulated identical tablets in the morn-
ing, one at lunchtime and three at teatime.
The medications will be supplied by SCM Pharma and
fully QP released in line with MHRA regulations and
cGMP procedures. SCM pharma will produce all patient
kits according to the randomisation list and will supply
code break envelopes to ensure patient safety.
The medications are being supplied in two packing
campaigns, with a shelf life of 12 months. The study
medications will be stored and dispensed by the trials
site pharmacy in accordance with Good Clinical Practice
and Good Manufacturing Guidelines. All the partici-
pants will receive a Medication Diary Sheet where they
will keep a daily record of the numbers of tablets taken
during the six week period.
Randomisation
A randomisation list will be computer generated by the
trial statistician (PS). Participants will be block rando-
mised in blocks of 9 and will be stratified by type of IBS
(i.e. diarrhoea predominant, constipation predominant,
alternating- pattern) as there may be a different
response to the medications between these sub-groups.
The Company who are supplying the trial medications
will make up the patient packs according to a randomi-
sation list supplied by the statistician so that the
research nurse is not aware of which trial medication
the participant receives. At randomisation, the research
nurse gives the participant the next sequential num-
bered pack from the appropriate strata of IBS type for
that participant’s symptoms.
Data collection
Participant data will be collected on the MIBS trial web-
site. Baseline data will be collected from included
patients before randomisation and will be co-ordinated
by the trial manager who will be blind to treatment allo-
cation. All baseline and outcome data is patient self-
completed away from the study team, thus avoiding any
influence of the study team on the responses and redu-
cing bias. Participants will be given a unique password
to log onto the website. Their data will be identified by
a unique identification number and will be kept separate
from any personal identifying data to maintain
confidentiality.
An on-line baseline assessment which includes socio-
demographic details and the measures detailed below will
be completed by all participants prior to the nurse visit
and before randomisation. These are well-recognised,
validated measures that are widely used and will enable
us to gain a clear picture of participants IBS and the
impact it has on their lives.
Those randomised to the self management programme
will complete on-line symptom severity questions, symp-
tom, food and exercise diaries, questions about stress
and triggers and their symptoms and their coping strate-
gies. These data will be collected and stored and may be
used to provide information to assess the self manage-
ment programme but will mostly be used by the partici-
pants themselves to monitor their progress and inform
themselves about their own symptoms, triggers and cop-
ing strategies as part of the cognitive behavioural ther-
apy based self-management programme.
Outcome data and questionnaires outlined below will
be completed at 6 and 12 weeks post randomisation by
all participants. Participants will be sent a reminder
email at 6 and 12 weeks to prompt them to complete
the questionnaires. If it has not been completed within
one week of the reminder, a further reminder will be
sent. One week after that, if no data has been entered,
the research nurse will ring the participant to ask if she
can collect the data over the telephone.
The patients GP notes will be reviewed at 12 weeks to
assess the number of GP contacts in the year prior to
entering the study and in the 3 months since the study.
In a full trial a one year notes review is planned. Other
studies have shown an impact on GP contacts from
patient self management programmes [22].
Study Procedures: (See Additional File 1)
Those responding to the recruitment letter from their
GP will be asked to complete a screening on-line ques-
tionnaire consisting of the Rome III criteria and ques-
tions about exclusion and inclusion criteria to check if
they fulfil the eligibility criteria for the study. They will
log on to the MIBS trial website with a unique ID num-
ber. Any patient indicating they may have a ‘red flag’
symptom that would indicate the need for further inves-
tigations (i.e. unexplained weight loss or rectal bleeding)
will be referred back to their GP and would not enter
the study.
Those who are eligible to enter the trial will be tele-
phoned by the research nurse and offered a meeting
with the research nurse at their GP practice to discuss
the trial and complete consent forms. At this meeting a
blood sample will be taken from the participant by
the research nurse for a full blood count (FBC),
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protein (CRP) to exclude alternative diagnoses i.e. anae-
mia that requires further investigation and Coeliac dis-
ease. The results will be made available to the
participants GP. The blood sample will not be stored for
future use.
Once the blood test result is known and the patients
eligibility for the trial is confirmed (i.e. no abnormalities
on the blood test) a further nurse appointment will be
made and the participant will be given a recruitment
pack containing their trial medication and an informa-
tion sheet about the website and website password, or
written patient information on IBS. If the blood tests
show an abnormal result i.e. an CRP over the normal
laboratory range or anaemia or a positive test for Coe-
liac disease the patient will not be randomised to the
trial but will be referred back the their GP for further
assessment.
The research nurse will telephone all participants in
the trial in the first week after randomisation (see ran-
domisation procedure above) to check they have no pro-
blems with the medication or paperwork and to ensure
they can log onto the MIBS website. The nurse will also
m a k eat i m ef o rap h o n ec a l ls e s s i o nw i t ht h o s er a n d o -
mised to the Regul8 self-management programme with
nurse support (see section above for details on tele-
phone session protocol and timing). They will also be
able to email the nurse regarding queries about the web-
site programme during the study. Medical questions will
not be addressed by the research nurse and participants
will be advised to seek medical advice if they have medi-
cal queries. Those randomised to website alone will be
offered technical website support by email.
T h o s en o tr a n d o m i s e dt or e c e i v et h ew e b s i t ep r o -
gramme will receive normal GP care. All the rando-
mised participants will receive normal GP care during
the trial if they require it.
The trial medication for the MIBS Study is over-
encapsulated to maintain blinding but is quite large and
preliminary work indicated that some participants may
find it difficult to swallow. If participants were consider-
ing withdrawal from the trial due to the size of the med-
ication and swallowing problems, they will be permitted
to open the medication capsules to enable them to con-
tinue to take the medication and stay within the trial.
The Research Nurse (RN) will discuss medication taking
with any participants who indicate that they are finding
it difficult to take. If they indicate that they cannot man-
age to take the trial medication because of swallowing
problems with the capsules, the RN will provide the
option that they could open the capsules by twisting
them and taking the medication inside the capsule. This
is smaller than the entire capsule and thus would mean
the medication is easier to swallow and should enable
retention of these participants within the study.
These participants will potentially be un-blinded as
they will see the tablets. However, participants will be
recording their medication taking in diaries and will be
asked to guess which medication they are on - enabling
assessment as to whether opening the capsule un-blinds
the participants. We will record which participants open
the capsules. Intention to treat analysis will be main-
tained but will include the opening of the capsules as
factor within the analysis of the data.
Primary Outcome measures
Change in the Irritable Bowel Symptom Severity Scale
(IBS SSS score) and IBS Quality of Life Questionnaire
(IBS-QOL) from baseline to 12 weeks.
The IBS SSS [23] is a 5 item self-administered ques-
tionnaire measuring: severity of abdominal pain, dura-
tion of abdominal pain, abdominal distension/tightness,
bowel habit, quality of life. Maximum score 500: < 75
normal bowel function, 75-174 mild IBS, 175-299 mod-
erate IBS, 300-500 severe IBS). The IBS-QOL [24] is an
extensively validated quality of life measure for IBS: 34
items, 8 subscales, item responses graded on a 5 point
scale, total score 0-100 with higher scores indicating
better health related QOL. Administered at baseline and
6 weeks (end of treatment) and12 weeks (6 months and
12 months would also be planned for the full trial).
Secondary outcome measures
The Subjects Global Assessment of Relief (SGA of
Relief) [25] is frequently used in treatment trials to iden-
tify IBS responders to therapy. Participants rate their
relief from IBS symptoms on a scale of 1 to 5 ranging
from “completely relieved” to “worse”. Scores are dichot-
omized so that patients scoring from 1-3 are considered
responders and those 4-5, non-responders.
The Hospital Anxiety and Depression Scale (HADS)
[26] is a commonly used self-report instrument for
detecting depression and anxiety in patients with medi-
cal illnesses. It enables assessment of participants’ level
of anxiety and depression which has shown to be high
in many patients with IBS.
Patient Enablement Questionnaire [27] assesses parti-
cipants’ ability to cope with their illness and life. The
number of Primary Care consultations for IBS will also
be assessed to look for any change. Other studies have
shown an impact on GP contacts from patient self man-
agement programmes [22].
The acceptability of the Regul8 self-management treat-
ment will be assessed using three questions where
patients rate the overall effectiveness of the programme,
the efficacy of programme compared to other treatments
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programme.
Qualitative interviews will also be undertaken at the
end of treatment with a small number of the partici-
pants regarding their experience of participating in the
trial and the acceptability of the trial procedures, includ-
ing the medication taking. This will provide richer and
more detailed information on the trial experience and
provide valuable information to inform a full trial.
Up to 30 participants will be invited to participate,
using purposive sampling to ensure we sample people
with a range of age, gender, symptoms and treatment
combinations. The interviews will be semi-structured
with open ended questions covering the following
topics: Main reasons to try out the treatment; Expecta-
tions of the treatment before initially trying it; Positive
and negative perceptions of the treatment; Changes dur-
ing and after the end of treatment; Looking back at the
treatment (thoughts and feelings). The set of generic
questions will be repeated for each treatment type that
is mentioned by the participants and for the interven-
tion received during the trial.
All interviews will be tape-recorded and full tran-
scribed, and inductive (data driven) thematic analysis
will be used to analyse the data following the methods
described by Boyatzis (1998) [28], Braun and Clarke
(2006) [29], and Joffe and Yardley (2004) [30].
Sample size
The aim of the pilot is to have sufficient numbers to test
the feasibility of the trial and assess crude differences
between the groups. Assuming an initial mean symptom
score of 250 (SD 80) in all groups, 35 patients are
required in each group to detect a difference in score of
53 points (2/3 of a SD of 80) between the treatment
groups (mebeverine, methylcellulose and placebo) or the
three website groups (none, minimal support, telephone)
for 80% power and 95% confidence. Allowing for drop
outs at 20%, 130 participants would be needed. If 135
are recruited each of the 9 randomisation groups would
potentially have 15 recruits.
For IBS-QOL, 34 would be required in each group to
detect a 10 point change in the IBS-QOL in the inter-
vention group assuming a score in the placebo group of
60 (SD of 15). Hence, allowing for a 20% drop-out rate,
again 135 participants would be more than sufficient.
Basis of assumptions for power calculation
The Kennedy [12] paper (2005) using the symptom
score in general practices in London found a baseline
symptom score of approximately 300 (SD 80) in the IBS
SSS in their trial of cognitive behavioural therapy and
mebeverine and a treatment effect of a 68 point reduc-
tion for CBT and mebeverine together over mebeverine
alone at 6 weeks after the CBT. (Their a priori power
calculation was on the basis of a score of 180 (SD80) in
the control group and 133 (SD80) in the CBT (treat-
ment) group at 6 months follow up.)
The IBS-QOL overall score was found to be 63.2 (SD
18.5) in validation scores for the measure [24], and a pre-
treatment score of 65.8 (SD19.9) with a post-treatment
score 10.2 points higher was found in further validation
of the measure in female patients with functional bowel
disorder in secondary care assessing cognitive beha-
vioural or patient education versus desipramine or
placebo [31].
Analysis
An intention-to-treat analysis, of change in the IBS SSS
and IBS-QOL at baseline, 6 weeks and 12 weeks (6
mnth and 1 yr are planned for the full trial) will be
undertaken by ANCOVA for a factorial trial. In the
main trial (but not in the pilot): subgroup analysis will
be performed using regression modelling to determine if
symptoms subgroup (diarrhoea-predominate, constipa-
tion-predominate and alternating symptoms) predicts
differences in outcome. Other potential factors that may
affect outcome will be explored: severity of presenting
symptoms, duration of presenting symptoms, age and
sex.
Ethical approval
The study has been reviewed and approved by South-
ampton Research Ethics Committee A number: 09/
H0502/101
MHRA approval
The Study has been reviewed and approved by the
MHRA. EudraCT number: 2009-013426-16
Trial Sponsorship
Provided by the University of Southampton
Trial Funder
Research for Patient Benefit Programme, National Insti-
tute of Health Research, NHS, UK
Safety Reporting
Adverse events will be recorded in accordance with the
University of Southampton Research Related Adverse
Event Reporting Policy and with the European Directive
2001/20/EC.
Monitoring and Audit
The study will be monitored and audited in accordance
with Southampton University procedures. All trial
related documents will be made available on request for
monitoring and audit by the University of Southampton,
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Page 7 of 9the relevant REC and for inspection by the MHRA or
other licensing bodies.
Data Protection
Data will be collected and retained in accordance with
the Data Protection Act 1998.
Storage of Records
Study documents (paper and electronic) will be retained
in a secure location during and after the trial has fin-
ished. All source documents will be retained for a per-
iod of 5 years following the end of the study.
Indemnity
This is an NHS-sponsored research study. For NHS
sponsored research HSG(96)48 reference no. 2 refers. If
there is negligent harm during the clinical trial when
the NHS body owes a duty of care to the person
harmed, NHS Indemnity covers NHS staff, medical aca-
demic staff with honorary contracts, and those conduct-
ing the trial. NHS Indemnity does not offer no-fault
compensation and is unable to agree in advance to pay
compensation for non-negligent harm. Ex-gratia pay-
ments may be considered in the case of a claim.
A Steering committee, including a patient representa-
tive, will oversee the trial procedures and ensure good
conduct of the study; they will meet at least annually.
The roles and responsibilities of each member of the
team
HE will be principal investigator and oversee the run-
ning of the study with support from PL. LY will oversee
the website development, RMM will oversee adaptation
of the CBT programme to a web-based format and
supervision of the nurse delivered intervention.
Regular updates and meetings will ensure good com-
munication. The collaborators will meet at least 4 times
ay e a r .T h er e s e a r c ha s s i s t a n tw i l lc i r c u l a t eam o n t h l y
update to review progress relative to the project plan,
highlighting any issues that need to be addressed. Each
team member will consult the other team members
immediately by email and/or phone on any issues that
arise.
Trial status
The trial opened to recruitment in April 2010 and
recruitment and follow up will continue until February
2011. Results will be analysed and reported in 2011.
Discussion
IBS is a common problem managed largely in general
practice. Many patients live with significant restrictions
on their daily activities and reduced quality of life.
There is a lack of research evidence on the commonly
prescribed medications and a lack of availability of psy-
chological therapies such as CBT which have been
shown to be beneficial in IBS. Provision of a web-based
CBT self-management programme for IBS patients has
the potential to open up new resources for IBS patients
with minimal additional cost in an area where there is
significant ill-health burden. Clarifying the effectiveness
of commonly prescribed medications will allow better
informed prescribing decisions and targeting of NHS
resources.
This pilot study is the first to look at providing CBT
as a web-based self-management programme for
patients with IBS. The factorial design allows the effec-
tiveness of common IBS medications to be assessed at
the same time, maximising the amount of data collected.
The trial will answer important questions regarding the
feasibility of undertaking this type of research, which
requires the involvement of large numbers of patients
from many GP practices across different PCTs. Trial
systems will be tested and data will be collected about
recruitment and drop-out rates, reasons for declining to
take part, acceptability of the medication and of the out-
come measures. Data on the variance and estimated
effects of the intervention will also be able to be
assessed. It will also provide guidance on the amount of
support/therapist time that is likely to be required for
the self-management programme. The qualitative data
will highlight useful changes in the self-management
programme or the study design for a larger trial. This is
a pilot study and the feasibility issues will be the main
useful outcomes as the trial is not powered to detect a
definitive effects size. It will however, have power to
demonstrate whether there are moderate to large effects.
T h et r i a lm e t h o d sc o m p l yw i t hb e s tp r a c t i c ef o rt h e
conduct and reporting of RCTs and thus will provide
good quality data and will be able to be replicated on a
larger scale.
Additional material
Additional File 1: Patient flow and data management diagram.T h i s
diagram is a detailed summary of the main steps and procedures of the
trial following a chronological order.
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